High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1166-1171

  Hosing, C ^a   Saliba, R M ^a   Okoroji, G J ^a   Popat, U ^a   Couriel, D ^a   Ali, T ^a   De Padua Silva, L ^a   Kebriaei, P ^a   Alousi, A ^a   De Lima, M ^a   Qazilbash, M ^a   Anderlini, P ^a   Giralt, S ^a   Champlin, R E ^a   Khouri, I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous transplant; Elderly; Non Hodgkin's lymphoma

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; LACTATE DEHYDROGENASE; MELPHALAN; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; COMORBIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 44949203469     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm608     Document Type: Article

References (26)

1. Armitage J. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-1030.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
3. Armitage JO, Vose JM, Bierman PJ et al. Salvage therapy for patients with lymphoma. Semin Oncol 1994; 21: 82-85.
4. Vose JM, Rizzo DJ, Tao-Wu J et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10: 116-127.
5. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498.
6. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
7. Thieblemont C, Coiffier B. Lymphoma in older patents. J Clin Oncol 2007; 25: 1916-1923.
8. Olivieri A, Capelli D, Montanan M et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: A single center experience. Bone Marrow Transplant 2001; 27: 1189-1195.
9. Stamatoullas A, Fruchart C, Khaltallah S et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31-35.
10. Moreau P, Milpied N, Voillat L et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65.years: A pilot study. Bone Marrow Transplant 1998; 21: 1193-1196.
11. Gopal AK, Gooley TA, Golden JB et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593-599.
12. Zallio F, Cuttica A, Caracciolo D et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 448-453.
13. Bitran JD, Klein L, Link D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383-388.
14. Buadi FK, Micallef IN, Ansell SM et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017-1022.
15. Leger CS, Bredeson C, Kearns B et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204-210.
16. Villela L, Sureda A, Canals C et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300-305.
17. Jantunen E, Itala M, Juvonen E et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis. Bone Marrow Transplant 2006; 37: 367-372.
18. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
19. Khouri IF, Saliba RM, Hosing C et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247.
20. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
21. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
24. StataCorp: Stata Corporation, StataCorp: Stata Statistical Software. Release 7.0. Stata Corporation, College Station, TX: 2001; 2001.
25. Giles FJ, Borthakur G, Ravandi F et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136; 624-627.
26. Etienne A, Esterni B, Charbonnier A et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109: 1376-1383.